- Home
- CMPR vs BEAM Comparison
CMPR vs BEAM Comparison
Compare CMPR & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMPR
- BEAM
- Stock Information
- Founded
- CMPR 1994
- BEAM 2017
- Country
- CMPR Ireland
- BEAM United States
- Employees
- CMPR N/A
- BEAM N/A
- Industry
- CMPR Publishing
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CMPR Consumer Discretionary
- BEAM Health Care
- Exchange
- CMPR Nasdaq
- BEAM Nasdaq
- Market Cap
- CMPR 2.0B
- BEAM 1.9B
- IPO Year
- CMPR N/A
- BEAM 2020
- Fundamental
- Price
- CMPR $70.07
- BEAM $24.70
- Analyst Decision
- CMPR Strong Buy
- BEAM Buy
- Analyst Count
- CMPR 2
- BEAM 10
- Target Price
- CMPR $114.50
- BEAM $47.67
- AVG Volume (30 Days)
- CMPR 130.3K
- BEAM 1.1M
- Earning Date
- CMPR 01-29-2025
- BEAM 02-25-2025
- Dividend Yield
- CMPR N/A
- BEAM N/A
- EPS Growth
- CMPR N/A
- BEAM N/A
- EPS
- CMPR 5.90
- BEAM N/A
- Revenue
- CMPR $3,339,531,000.00
- BEAM $349,643,000.00
- Revenue This Year
- CMPR $7.63
- BEAM N/A
- Revenue Next Year
- CMPR $5.45
- BEAM $10.82
- P/E Ratio
- CMPR $11.88
- BEAM N/A
- Revenue Growth
- CMPR 6.57
- BEAM 328.73
- 52 Week Low
- CMPR $58.05
- BEAM $20.84
- 52 Week High
- CMPR $104.92
- BEAM $49.50
- Technical
- Relative Strength Index (RSI)
- CMPR 31.46
- BEAM 41.30
- Support Level
- CMPR $70.22
- BEAM $24.96
- Resistance Level
- CMPR $85.56
- BEAM $29.52
- Average True Range (ATR)
- CMPR 2.87
- BEAM 1.64
- MACD
- CMPR -0.78
- BEAM -0.51
- Stochastic Oscillator
- CMPR 8.73
- BEAM 9.71
About CMPR Cimpress plc (Ireland)
Cimpress PLC invests in and builds customer-focused, entrepreneurial, mass-customization businesses for the long term. Mass customization seeks to produce goods and services to meet individual customer needs with near mass production efficiency. Its products and services include a broad range of marketing materials, business cards, signage, promotional products, logo apparel, packaging, books and magazines, wall decor, photo merchandise, invitations and announcements, design and digital marketing services, and other categories. The company's segment includes Vista; PrintBrothers; The Print Group; National Pen and All Other Businesses. It generates maximum revenue from the Vista segment.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.